on PharmaSGP Holding SE (isin : DE000A2P4LJ5)
PharmaSGP Reports Strong Growth in Q1 2024
PharmaSGP Holding SE, a German OTC pharmaceutical company, announced a robust start to 2024 with a revenue increase of 25.6% in Q1, reaching €30.1 million, up from €24.0 million in the same quarter of the previous year. This growth follows an impressive performance in 2023.
The company's adjusted EBITDA for the quarter rose by 26.5% to €8.9 million, compared to €7.0 million in Q1 2023. The adjusted EBITDA margin slightly improved to 29.4% from 29.2%.
CEO Natalie Weigand expressed pride in the company’s ability to continue its rapid growth, largely attributing success to effective marketing strategies and a strong platform model. CFO Michael Rudolf highlighted the success in international markets and anticipates continued profitable growth with projected revenues between €107.0 million and €112.0 million for 2024.
The full financial report for the first quarter will be released on May 28, 2024.
R. P.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PharmaSGP Holding SE news